Literature DB >> 29514582

A case of an acute cutaneous drug reaction with hydroxychloroquine.

Amritakaur Randhawa1, Grant Wylie2.   

Abstract

Hydroxychloroquine is considered a relatively benign drug and is regularly used by rheumatologists and dermatologists. We highlight the severe adverse drug reaction potential of this commonly prescribed medication. We report the case of a 63-year-old male, who presented with widespread skin eruption following initiation of hydroxychloroquine two weeks earlier for an inflammatory arthritis. He had typical clinical, biochemical and histological features of the now recognised formal 'diagnosis' of severe cutaneous adverse drug reaction. The culprit drug was stopped and he responded to oral and topical steroids as well as supportive measures. Severe reactions to hydroxychloroquine are uncommon; however, as in this case, drug hypersensitivity reactions often manifest in skin. In a drug normally considered to be safe, these potential cutaneous side effects should be highlighted in information given to patients prior to commencement.

Entities:  

Keywords:  Hydroxychloroquine; drug rash with eosinophilia and systemic symptoms; severe cutaneous adverse drug reactions

Mesh:

Substances:

Year:  2018        PMID: 29514582     DOI: 10.1177/0036933018763277

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  2 in total

Review 1.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

2.  Exanthema and eosinophilia in COVID-19 patients: has viral infection a role in drug induced exanthemas?

Authors:  A M Rosell-Díaz; A Mateos-Mayo; L M Nieto-Benito; I Balaguer-Franch; E Hernández de la Torre-Ruiz; A Lainez-Nuez; R Suárez-Fernández; M Bergón-Sendín
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-30       Impact factor: 9.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.